Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Puccini?s ?exotic inspiration?:Unusual source of Madam Butterfly's melodies revealed

  • Online reader comments can provide valuable feedback to news sites

  • Pinpointing mutations in a relapsed children's cancer may lead to improved treatments

  • Infection with Wolbachia bacteria curbs fighting among fruit flies

  • Rapid response to kids' stroke symptoms may speed diagnosis

  • Commonly prescribed drugs affect decisions to harm oneself and others

  • Long-term memories are maintained by prion-like proteins

  • Do you really think you're a foodie?

  • Water to understand the brain

  • Can autism be measured in a sniff?

  •